N-Boc-3-哌啶甲酸甲酯 | 148763-41-1

• 物质功能分类: 化学试剂 - 有机试剂 - 酯类
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: N-Boc-3-哌啶甲酸甲酯
• 中文别名: N-Boc-哌啶-3-甲酸甲酯；N-BOC-3-哌啶甲酸甲；N-叔丁氧羰基-3-哌啶甲酸甲酯；1-叔丁氧羰基-3-哌啶甲酸甲酯；BOC-3-哌啶甲酸甲酯；1-BOC-哌啶-3-甲酸甲酯；N-BOC-3-哌啶甲酸甲酯
• 英文名称: 1-tert-butyl 3-methyl piperidine-1,3-dicarboxylate
• 英文别名: Methyl N-Boc-piperidine-3-carboxylate；1-O-tert-butyl 3-O-methyl piperidine-1,3-dicarboxylate
• CAS: 148763-41-1
• 化学式: C₁₂H₂₁NO₄
• mdl: MFCD06795926
• 分子量: 243.303
• InChiKey: LYYJQMCPEHXOEW-UHFFFAOYSA-N

物化性质

• 熔点：
  47.0 to 51.0 °C
• 沸点：
  307.4±35.0 °C(Predicted)
• 密度：
  1.094±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.833
• 拓扑面积：
  55.8
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2933399090
• 危险类别码：
  R36/37/38
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  存放于惰性气体中，并避免接触湿气（否则可能发生分解）。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Methyl N-BOC-piperidine-3-carboxylate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Methyl N-BOC-piperidine-3-carboxylate
CAS number: 148763-41-1

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C12H21NO4
Molecular weight: 243.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  N-Boc-3-哌啶甲酸甲酯 在 lithium aluminium tetrahydride 、 Glauber's salt 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 以99%的产率得到1-Boc-3-羟甲基哌啶
  参考文献：
  名称：

  2-SUBSTITUTED-ETHYNYLTHIAZOLE DERIVATIVES AND USES OF SAME

  摘要：

  本发明提供了公式（I）的2-取代-乙炔基噻唑衍生物：其中R1、R2和X如此处定义，或其药学上可接受的盐；以及使用相同的药物组合物和方法。

  公开号：

  US20110092475A1
• 作为产物：
  描述：

  3-哌啶甲酸 在 氯化亚砜 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 19.0h， 生成 N-Boc-3-哌啶甲酸甲酯
  参考文献：
  名称：

  56 个形状多样的 3D 片段的设计和合成。

  摘要：

  基于片段的药物发现现已广泛应用于制药行业的先导化合物开发。然而，片段筛选集合通常主要由扁平的二维分子组成。在此，我们描述了设计和合成 56 个 3D 二取代吡咯烷和哌啶片段的工作流程，这些片段占据了片段空间中代表性不足的区域（如主惯性矩 (PMI) 分析所示）。该片段集合的一个关键且独特的基础设计特征是在合成和合成之前对片段形状和构象多样性进行评估（通过考虑比全局最小能量构象异构体的能量高出高达 1.5 kcal mol -1的构象）。也用于选择合成目标。3D 片段被设计为包含合适的合成手柄，以供将来的片段精加工使用。最后，通过将我们的 3D 片段与六个商业图书馆进行比较，很明显我们的馆藏具有较高的三维度和形状多样性。

  DOI：

  10.1002/chem.202001123
• 作为试剂：
  描述：

  1-BOC-哌啶-3-羧酸 、 三甲基硅烷化重氮甲烷 在 N-Boc-3-哌啶甲酸甲酯 作用下， 以 Toluol, Methanol 为溶剂， 以to yield 4.44 g (83.7%) of piperidine-1,3-dicarboxylic acid 1-tert-butyl ester-3-methyl ester (Intermediate 53)的产率得到N-Boc-3-哌啶甲酸甲酯
  参考文献：
  名称：

  Therapeutic Pyrazolo[3,4-b]Pyridines and Indazoles

  摘要：

  本发明提供了I式化合物：其中R2、R3、R4、R5、R6、R7、X和L具有规范中定义的任何值，以及其药学上可接受的盐，可用作治疗中枢神经系统障碍和疾病的药物，包括注意力缺陷多动障碍、神经病性疼痛、尿失禁、焦虑、抑郁、精神分裂症和纤维肌痛的药物。还提供了包含一种或多种I式化合物的制药组合物。

  公开号：

  US20080293715A1

文献信息

• [EN] PREPARATION AND USES OF PYRIMIDINONE DERIVATIVES<br/>[FR] PRÉPARATION ET UTILISATIONS DE DÉRIVÉS DE PYRIMIDINONE
  申请人：CANCER RESEARCH TECH LTD

  公开号：WO2018055402A1

  公开（公告）日：2018-03-29

  The present invention relates to compounds of formula (I), and salts and solvates thereof, that function as inhibitors of cell division cycle 7 (Cdc7) kinase enzyme activity: (Formula (I)) wherein X, R1, R2, and n are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which Cdc7 kinase activity is implicated.

  本发明涉及式(I)的化合物，以及其盐和溶剂合物，其作为细胞分裂周期7（Cdc7）激酶酶活性的抑制剂：（式(I)）其中X，R1，R2和n如本文所定义。本发明还涉及制备这些化合物的方法，包括它们的药物组合物，以及它们在治疗增殖性疾病（如癌症）以及其他涉及Cdc7激酶活性的疾病或病况中的用途。
• [EN] BENZAMIDE IMIDAZOPYRAZINE BTK INHIBITORS<br/>[FR] COMPOSÉS BENZAMIDES ET IMIDAZOPYRAZINES UTILISÉS COMME INHIBITEURS DE LA BTK
  申请人：MERCK SHARP & DOHME

  公开号：WO2016106623A1

  公开（公告）日：2016-07-07

  Provided are Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I, pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, or their use in therapy.

  提供的是根据式I的布鲁顿酪氨酸激酶（Btk）抑制剂化合物、其药学上可接受的盐、含有它们的药物组合物或其在治疗中的用途。
• Novel norepinephrine reuptake inhibitors for the treatment of central nervous system disorders
  申请人：Caprathe William Bradley

  公开号：US20050096327A1

  公开（公告）日：2005-05-05

  This invention relates to compounds of the formula 1 wherein R 1 , R 2 , and R 3 and R 4 are defined as in the specification, pharmaceutical compositions containing them and their use in the treatment of central nervous system disorders.

  这项发明涉及公式1的化合物 其中R 1 ，R 2 ，R 3 和R 4 如规范中所定义，包含它们的药物组合物以及它们在治疗中枢神经系统疾病中的用途。
• [EN] CYANO-SUBSTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30<br/>[FR] HÉTÉROCYCLES CYANO-SUBSTITUÉS PRÉSENTANT UNE ACTIVITÉ EN TANT QU'INHIBITEURS DE L'USP30
  申请人：MISSION THERAPEUTICS LTD

  公开号：WO2018065768A1

  公开（公告）日：2018-04-12

  The present invention relates to cyano-substituted-heterocycles of Formula (I) with activity as inhibitors of deubiquitilating enzymes, in particular, ubiquitin C-terminal hydrolase 30 or ubiquitin specific peptidase 30 (USP30), having utility in a variety of therapeutic areas including cancer and conditions involving mitochondrial dysfunction. (Formula (I))

  本发明涉及具有抑制去泛素化酶活性的Formula (I)的氰基取代杂环化合物，特别是泛素C-末端水解酶30或泛素特异性肽酶30（USP30），在包括癌症和涉及线粒体功能障碍等各种治疗领域中具有用途。（Formula (I)）
• [EN] PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS<br/>[FR] PYRIMIDYL CYCLOPENTANES EN TANT QU'INHIBITEURS DE PROTÉINE KINASE AKT
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2009089454A1

  公开（公告）日：2009-07-16

  The present invention provides compounds of Formula (I) including tautomers, resolved enantiomers, resolved diastereomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof. Also provided are methods of using the compounds of this invention as Akt protein kinase inhibitors and for the treatment of Akt-mediated diseases, for example, hyperproliferative diseases such as cancer.

  本发明提供了式（I）的化合物，包括互变异构体、已分离的对映体、已分离的非对映异构体、溶剂合物、代谢物、盐以及其药学上可接受的前药。本发明还提供了使用这些化合物作为Akt蛋白激酶抑制剂以及用于治疗Akt介导的疾病，例如，高增殖性疾病如癌症的方法。